JPRN-jRCT2080224529已完成2 期
A phase II study evaluating combination treatment of TAS-102 and Ramucirumab in patients with unresectable advanced or recurrent gastric cancer.
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Has provided written informed consent
- •2. 20 years and over of age on the day of signing informed consent
- •3. Has histologically confirmed unresectable, advanced or recurrent gastric cancer
- •4. Is able to take medications orally
- •5. Is ECOG PS 0 or 1
- •6. Has negative pregnancy test
- •7. Has adequate organ function value
- •8. Is willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other protocol procedures
排除标准
- •1. Had previously received TAS-102
- •2. Is pregnant or breast-feeding
- •3. Is inappropriate for enrolment into this study in the investigator's judgment
研究者
相似试验
已完成
2 期
Phase II study comparing combination therapy with carboplatin plus pemetrexed vs combination therapy with pemetrexed plus bevacizumab in chemo-naive elderly patients with advanced non-squamous non-small-cell lung cancer (HSR1402).advanced non-squamous non-small-cell lung cancerJPRN-UMIN000014302Hamamatsu Univ. School of Medicine64
已完成
2 期
Multicenter Phase II study of combination therapy with S-1 plus Irinotecan plus Cetuximab (MetronomicIRIS/Cmab combination therapy) in patients with KRAS wild type unresectable colorectal cancer, who had previously received on fluoropyrimidine , oxaliplatin , irinotecan and bevacizumab. (KSCOG CR-06)Colorectal cancerJPRN-UMIN000012063Kurume University Medical Center30
已完成
2 期
Multicenter phase II study of combination therapy with oral S-1 plus cisplatin in elderly patients with metastatic gastric cancerElderly patients with metastatic gastric cancerJPRN-UMIN000009349ational Cancer Center Hospital40
已完成
1 期
Phase I/II study on combination therapy consisting of a fixed dose-rate infusion of gemcitabine with oral fluorinated pyrimidine compound S-1 (FGS) in patients with gemcitabine-refractory advanced pancreatic cancerPatients with gemcitabine-refractory metastatic pancreatic cancerJPRN-C000000450ational Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division40
进行中（未招募）
不适用
Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor (ATX-study) - ATXEUCTR2006-006058-83-NLVU Medisch Centrum